Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 550 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non Alcoholic Fatty Liver Diseases (NAFLD) Clear all
Completed Phase 2 Interventional Results available

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

NCT03987451
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
Chandler, Arizona • Peoria, Arizona • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 24, 2026, 2:45 AM EDT
Not listed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

NCT03205345
View directory record Official record
Conditions
Decompensated Cirrhosis
Interventions
Emricasan (25 mg), Emricasan (5 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
76
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 24, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH

NCT02279524
View directory record Official record
Conditions
Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses
Interventions
Aramchol
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
Chula Vista, California • Los Angeles, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 24, 2026, 2:45 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT01289639
View directory record Official record
Conditions
Fatty Liver
Interventions
fenofibrate, pioglitazone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 24, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

NCT03213145
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
intraconazole, Rifampin, EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 24, 2026, 2:45 AM EDT
Not yet recruiting Phase 2 Interventional

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

NCT03867487
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
Interventions
Empagliflozin 10 MG, Placebo Oral Tablet
Drug
Lead sponsor
Justin Ryder
Other
Eligibility
12 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Completed No phase listed Observational

Ultrasound Quantification of Liver Fat

NCT04523584
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Magnetic Resonance Imaging (MRI), Ultrasound Imaging
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
16 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 24, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

NCT05232071
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Interventions
Lanifibranor, Placebo, Empagliflozin
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Homewood, Alabama • Chandler, Arizona • Conway, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Comparison of Dietary Sugar Reduction Methods

NCT04186793
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Guided Grocery Shopping (GGS), Diet Provision Group
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
8 Years to 16 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 24, 2026, 2:45 AM EDT
Not listed Phase 2 Interventional

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

NCT04880187
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
AXA1125, Placebo
Drug
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Cullman, Alabama • Tucson, Arizona • Canoga Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 24, 2026, 2:45 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
169
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NCT04328077
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
31
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 24, 2026, 2:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Obesity on Proton Pump Inhibitors

NCT04248335
View directory record Official record
Conditions
Pediatric Obesity, NAFLD, GERD
Interventions
Lansoprazole, Pantoprazole, Midazolam
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Years to 21 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet

NCT03141008
View directory record Official record
Conditions
Obesity, Fatty Liver, Ketogenic Dieting
Interventions
Fibroscan changes with different diets
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 24, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

NCT03783897
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305, Oral Contraceptive
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 24, 2026, 2:45 AM EDT
Completed No phase listed Observational

Genetics of Fatty Liver Disease in Children

NCT01966627
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
ogtt, genotyping, abdominal and liver magnetic resonance imaging, stool sample, liver biopsy
Other
Lead sponsor
Yale University
Other
Eligibility
7 Years to 18 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 24, 2026, 2:45 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

NAFLD in Adolescents and Young Adults With PCOS

NCT02506946
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
14 Years to 25 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

NCT04019561
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
MEDI0382 high dose, Placebo for MEDI0382 high dose, MEDI0382 low dose, Placebo for MEDI0382 low dose
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Tucson, Arizona • Canoga Park, California • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 24, 2026, 2:45 AM EDT
Withdrawn Not applicable Interventional

Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease

NCT05130346
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
Interventions
Mindfulness Based Stress Reduction (MBSR)
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 24, 2026, 2:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Collection Biorepository for Liver Disease Research

NCT03025074
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Withdrawn No phase listed Observational

Evaluation of Intestinal Microbiome in Obese Kids

NCT00816296
View directory record Official record
Conditions
Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Blood Draw, Stool collection, BodPod Measurement, Liver Ultrasound
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 24, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

NCT03517540
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Cenicriviroc (CVC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 24, 2026, 2:45 AM EDT
Not listed Not applicable Interventional

Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)

NCT01511523
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
RGMA001, Sugar Pill
Dietary Supplement
Lead sponsor
Biovil Research Group, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 24, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

NCT06176079
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions
Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush
Drug · Procedure
Lead sponsor
Michael Ohliger, MD PhD
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 24, 2026, 2:45 AM EDT